Leflunomide Aurobindo

Leflunomide, the active ingredient in Leflunomide Aurobindo, is an immunomodulatory agent presented as an oral tablet for oral use. It is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis and juvenile idiopathic arthritis in adult and pediatric patients where disease‑modifying therapy is required.

GNH USA supplies Leflunomide Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Leflunomide is a disease‑modifying antirheumatic drug that targets inflammatory pathways in autoimmune arthritis. - Rheumatoid arthritis: reduces joint inflammation and slows structural damage. - Psoriatic arthritis: improves skin lesions and joint symptoms. - Juvenile idiopathic arthritis: controls disease activity and prevents functional impairment.

Leflunomide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Diarrhoea: mild to moderate gastrointestinal upset. - Nausea and vomiting: transient digestive discomfort. - Alopecia: reversible hair thinning. - Rash or pruritus: skin irritation. - Elevated liver enzymes: mild hepatic enzyme rise. - Hypertension: increase in blood pressure readings.

Serious or Rare Side Effects: - Severe liver injury: hepatitis or hepatic failure. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: life‑threatening skin reactions. - Bone marrow suppression: pancytopenia or severe neutropenia. - Interstitial lung disease: progressive pulmonary fibrosis. - Serious infections: opportunistic bacterial or viral infections. - Teratogenicity: fetal malformations when exposure occurs in pregnancy.

Before initiating therapy, clinicians should assess baseline health status and monitor for specific risks. - Liver function monitoring: obtain baseline tests and repeat periodically. - Blood pressure assessment: check regularly and manage hypertension. - Pregnancy avoidance: contraindicated in pregnancy; ensure effective contraception. - Infection vigilance: screen for active infections and avoid live vaccines. - Drug‑specific counseling: inform patients about potential hair loss and gastrointestinal upset. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Leflunomide can alter the effect of several co‑administered medicines, requiring careful management.

Major Interactions (Avoid): - Warfarin: increased anticoagulant effect, risk of bleeding. - Methotrexate: additive hepatotoxicity and bone‑marrow suppression. - Azathioprine: heightened risk of severe cytopenias.

Moderate Interactions (Monitor Closely): - CYP2C9 inhibitors (e.g., fluconazole): may raise leflunomide plasma levels. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): potential for increased liver enzyme elevation. - Live vaccines: reduced efficacy and higher infection risk.